Celldex CDX527-01 (Solid tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug (CDX-527) is a safe and effective treatment for your cancer.

What is the Condition Being Studied?

Ovarian Cancer

Who Can Participate in the Study?

Adults who are diagnosed with ovarian cancer.

For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the study drug (CDX-527) by IV
- Give tumor tissue
- Have physical exams, blood and urine tests
- Have heart scans (ECG)
- Have radiographs (X-rays)
- Have imaging scans (MRI and or CT)

Study Details

Full Title
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX 527 in Patients with Advanced Malignancies
Principal Investigator
Protocol Number
IRB: PRO00105515
NCT: NCT04440943
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698